Apr 1 |
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Apr 1 |
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
|
Mar 19 |
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March
|
Mar 12 |
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
|
Mar 12 |
Fractyl stock slides amid preclinical data for diabetes gene therapy
|
Mar 12 |
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
|
Mar 3 |
Analysts Bet Big on These Beaten-Down IPO Stocks
|
Feb 27 |
BofA, Morgan Stanley bullish on newly public Fractyl Health
|
Feb 20 |
Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
|
Feb 2 |
Fractyl Health stock down 8% following $110M IPO
|